324 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
14 Aug 23
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
4:11pm
patent litigation
New management team in place
Reiterating full-year net product sales guidance for the oncology care franchise of $99-$103 million … and $43.0 million, respectively, for the same periods in 2022.
CINVANTI ANDA Litigation: Heron recently had a favorable outcome at the Markman hearing
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
14 Nov 23
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:10pm
, for the same periods in 2022.
CINVANTI ANDA Litigation: Heron had a favorable outcome at the Markman hearing in the pending Hatch-Waxman Abbreviated New … Drug Application litigation against Fresenius Kabi to enforce our CINVANTI patents. We are pleased with the outcome and will continue to vigorously
8-K
EX-99.1
rul01fn7lrz3fv6dmvcm
11 May 23
Net Product Sales for First Quarter of 2023 Grew 26% to $29.6 million, Compared to First Quarter Net Product Sales in 2022
4:06pm